Published on February 15, 2020
Scientists report promising activity of the novel an oral first-in-class MK-6482 drug that targets a key driver of clear cell Renal Cell Carcinoma (ccRCC) in patients with metastatic disease.
In the vast majority of patients with clear cell Renal Cell Carcinoma (RCC), a tumor suppressor protein known as Von Hippel-Lindau (VHL) is not functional. As a result, hypoxia inducible factor (HIF) proteins accumulate inside the tumor cell, wrongly signaling there is a shortage of oxygen and activating the formation of blood vessels, fueling tumor growth.
Understanding this abnormal process has paved the way for new cancer drugs – MK-6482 being one of them and is distinct in that it targets HIF-2a directly leading to blocking cancer cell growth, proliferation and abnormal blood vessel formation.
The study included 55 patients with advanced clear cell kidney cancer who had an average of 3 prior lines of therapies.
- Researchers from Dana-Farber Cancer Institute report that 24% of patients had their tumor shrunk given MK-6482 and it was seen in all risk categories – poor, intermediate and good and in a heavily refractory.
- 56% of patients had their disease stopped from growing and progressing.
- That brings us to 80% of patients who responded to MK-6482.
- The median time until progression under the treatment was 11 months.
MK-6482 was well-tolerated with a favorable safety profile.
Contact us to find out what is the best treatment for YOU
Because we, do not give up on life!
Contact us 24/7 for free service matching:
Call center +44.2082.426.039